Breast Cancer Trial, Recruiting NCT07624617 Sponsor: University of Minnesota Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07624617
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older
  • People who have been diagnosed with breast cancer that has spread to other parts of the body, confirmed through a tissue sample test
  • People who are menopausal, or whose ovaries have been medically suppressed (for example, through medication)
  • People currently taking capivasertib (2 tablets twice daily, 4 days per week)
  • People who have been on their current capivasertib dose without changes for at least 2 weeks
  • People with a functional ability rating of 0 or 1 on a standard medical scale, meaning fully active or able to carry out light activity (confirm with trial site)
  • People with a Body Mass Index (BMI) of 25 or above
  • People who are able to give their informed agreement to take part in the study
  • People who are willing to follow the study requirements, including wearing a continuous glucose monitor, tracking food intake through a mobile app, and making changes to their diet
  • People who have access to a smartphone or tablet to use the study's mobile application

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with Type 1 diabetes
  • People with Type 2 diabetes that is not well controlled (based on a specific blood sugar marker being above a certain level)
  • People with a history of severe low blood sugar episodes
  • People with eating disorders, or for whom fasting would be medically inadvisable
  • People who are pregnant or breastfeeding
  • People with significant digestive or gut conditions that affect how food is absorbed
  • People who are unable to fast for medical reasons
  • People who are already taking part in another study involving dietary changes
  • People who have had significantly abnormal blood test results within 4 weeks before agreeing to join, such as low red blood cell levels, low platelet counts, abnormal liver function, or reduced kidney function (confirm specific thresholds with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 1 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Effect of plasma from fasting in patients on PI3K inhibitors on cell viability; mechanisms by which fasting might enhance PI3K inhibitor efficacy through complementary molecular and cellular studies; Identify biomarkers/patient characteristics predicting the enhancement of PI3K inhibitor efficacy with fasting.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov